IRON Disc Medicine, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1816736 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-34.2%
TTM EPS YoY-18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.3%
ROA-36.6%
ROIC (approx.)-40.5%
Asset turnover—
Leverage & solvency
Liabilities / assets13.6%
Debt / equity0.10x
Current ratio20.30x
Interest coverage-61.10x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $44.08M | $46.93M | $45.90M | $46.22M | $50.33M | $46.32M | $27.76M | $24.80M |
| SG&A expense | $20.08M | $18.14M | $23.62M | $20.75M | $17.36M | $15.09M | $12.18M | $9.75M |
| Operating income | -$64.16M | -$65.08M | -$69.52M | -$66.97M | -$67.70M | -$61.41M | -$39.95M | -$34.55M |
| Interest expense | $1.71M | $908,000 | $844,000 | $883,000 | $917,000 | $910,000 | $897,000 | $572,000 |
| Pretax income | -$59.43M | -$59.46M | -$63.45M | -$60.44M | -$62.22M | -$55.20M | -$33.97M | -$29.28M |
| Income tax | $109,000 | $69,000 | $51,000 | $88,000 | $102,000 | $52,000 | $119,000 | $176,000 |
| Net income | -$59.53M | -$59.53M | -$63.50M | -$60.53M | -$62.32M | -$55.25M | -$34.09M | -$29.46M |
| EBITDA | -$64.07M | -$64.98M | -$69.44M | -$66.88M | -$67.61M | -$61.33M | -$39.93M | -$34.54M |
| EPS (basic) | -1.53 | -1.54 | -1.65 | — | -1.77 | -1.58 | -1.02 | — |
| EPS (diluted) | -1.53 | -1.54 | -1.65 | — | -1.77 | -1.58 | -1.02 | — |
| Weighted avg. shares (diluted) | 38.90M | 38.69M | 38.49M | — | 35.18M | 35.02M | 33.32M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $89.98M | $98.68M | $88.91M | $91.14M | $140.90M | $127.58M | $122.91M | $192.67M |
| Short-term investments | $592.83M | $619.07M | $641.25M | $700.01M | $475.26M | $522.64M | $571.99M | $297.45M |
| Current assets | $697.40M | $732.76M | $747.46M | $803.90M | $627.17M | $661.59M | $705.60M | $493.62M |
| PP&E, net | $890,000 | $980,000 | $1.07M | $1.16M | $1.23M | $1.29M | $1.37M | $751,000 |
| Total assets | $699.49M | $735.07M | $750.21M | $806.88M | $630.46M | $665.06M | $709.27M | $496.77M |
| Current liabilities | $34.36M | $30.36M | $31.14M | $36.64M | $26.74M | $20.61M | $18.74M | $23.32M |
| Long-term debt | $59.74M | $59.34M | $29.36M | $29.16M | $28.95M | $28.74M | $28.53M | $28.32M |
| Total debt | $59.74M | $59.34M | $29.36M | $29.16M | $28.95M | $28.74M | $28.53M | $28.32M |
| Total liabilities | $95.24M | $90.91M | $61.78M | $67.05M | $57.06M | $50.90M | $48.90M | $53.19M |
| Shareholders' equity | $604.25M | $644.16M | $688.43M | $739.83M | $573.39M | $614.16M | $660.36M | $443.59M |
| Net debt | -$30.24M | -$39.34M | -$59.55M | -$61.99M | -$111.96M | -$98.84M | -$94.39M | -$164.35M |
| Shares outstanding | 38.62M | 38.35M | 38.19M | 37.89M | 35.01M | 34.69M | 34.58M | 29.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$40.20M | -$44.20M | -$62.24M | -$43.30M | -$47.80M | -$47.92M | -$41.38M | -$27.57M |
| Capital expenditure | $0 | $0 | $0 | $20,000 | $26,000 | $36,000 | $851,000 | $449,000 |
| Free cash flow | -$40.20M | -$44.20M | -$62.24M | -$43.32M | -$47.83M | -$47.95M | -$42.23M | -$28.02M |
| Investing cash flow | $25.33M | $21.63M | $58.31M | -$222.89M | $49.54M | $51.69M | -$272.63M | -$1.43M |
| Financing cash flow | $6.18M | $32.34M | $1.70M | $216.68M | $11.59M | $892,000 | $244.25M | $28.80M |
| Depreciation & amortization | $90,000 | $90,000 | $89,000 | $89,000 | $87,000 | $85,000 | $20,000 | $9,000 |
| Stock-based compensation | $14.61M | $13.95M | $11.95M | $10.04M | $9.51M | $8.42M | $6.36M | $4.33M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.